Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: marvin friedman who wrote (615)	5/1/1999 9:38:00 PM
From: Jibacoa	Read Replies (2) \| Respond to of 2344

<<<I think we should cool it.>>> No need to cool it, since is not even warm yet.!!! But wait just a few weeks for some of the things that may put a fire under it: The ASCO conference starting on May 15th in San Diego. Look for results to be presented on use of THERATOPE breast vaccine on patients with metastatic Ca. after bone marrow transplant. Results of "bridging study" showing that the more potent version of the vaccine is more antigenic and doesn't seem to have any increased side effects. The shareholders meeting on May 26th, starting at 4 PM (after market's close.) The possible N.Y. Times article on cancer vaccines!!! Some highlights from the 1998 Annual Report: On page 2: Listing results of THERATOPE's phase II on breast cancer: 26.5 MONTHS SURVIVAL vs. 9.2 FOR CONTROLS On page 2: The new formulation of THERATOPE is 100 TIMES MORE POTENT than the original formulation.And FDA gave OK for bridging study. Interim data indicates that IMPROVED VERSION APPEARS AS SAFE AND MORE IMMUNOGENIC, AND MORE MATURE RESULTS ARE TO BE RELEASED in 1999. On page 2: Plans to take a look at interim results of ongoing phase III as early as 24 months from start(November98) That is just 18 MONTHS ahead. If the interim look at results demonstrates significant data, Biomira will probably RECEIVE ACCELERATED MARKETING APPROVAL !!! On page 10: The BLP25 in pre-clinical models prevented lung metastases when given prior to an injection of a cancer cell line expressing human MUC-1. In other experiments with BLP25, cancer cells were almost completely eradicated when it was administered after the cancer cells had established microscopic cancer nodules.!!! On page 11: Biomira developed a novel system for administering IL-2 by incorporating it in a liposome. Pre-clinical studies show that Liposomal IL-2 enhances the therapeutic effect of peptides vaccines. Biomira plans on testing Liposomal IL-2 in combination with a MUC-1 vaccine to potentially enhance the immune response to the vaccine.(Remember that the present vaccine is already 100 times more potent than the original) !!! That is like going from 10 megabytes to one Gigabyte. Biomira believes that Liposomal IL-2 can also be used in other cancer indications as well as certain infectious diseases such as AIDS !!! On page 11: About the LIPOSOMAL IDIOTYPIC VACCINES: Combining IL-2 with patient specific tumor antigens, obtained from cancer cells to produce a CUSTOMIZED VACCINE AGAINST THE PATIENT'S OWN CANCER CELLS. This holds the promise TO PRODUCE THE MOST EFFECTIVE CANCER TREATMENT EVER!!! Biomira has developed a novel lymphoma vaccine based on this liposomal idiotypic cancer model. This vaccine was developed under a collaboration research and development agreement between the US National Cancer Institute (NCI) and Biomira USA. Plans are to proceed to a Phase I clinical at NCI in association with Biovector Therapeutics of Tolouse, France THIS YEAR.!!! Preclinical data suggests that this type of PATIENT-SPECIFIC vaccine FAR EXCEEDS THE EXPECTATIONS OF OTHER PRODUCTS IN THE MARKET OR IN DEVELOPMENT FOR USE IN THE TREATMENT OF LYMPHOMA!!! Biomira is "THE CANCER VACCINE PEOPLE". !!!! DON'T COOL IT YET, because IT IS NOT EVEN WARM, but you better have the ice ready if you don't want to get burned, because IT IS GOING TO GET RED IRON HOT PRETTY SOON.!!! GOOD LUCK. Bernard